Post Profile






Study results offer another boon for PARP inhibitors in treatment of advanced breast cancer

(University of Pennsylvania School of Medicine) Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, M.D., executive director of the Basser Center for BRCA at Penn's Abramson Cancer Center, will present new results from the Mediola and OlympiAD trials showing continued success of treating BRCA-related metastatic breast cancer with the PARP inhibitor olaparib with limited side effects for patients.
read more

share

Related Posts


Roche lymphoma drug drives high remission rate, longer survival: study

Health : Reuters: Health

(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment ...

Penn effort to expand trials of olaparib leads to new treatment options for patients with advanced BRCA-related breast cancer

Health : EurekAlert: Health

(University of Pennsylvania School of Medicine) Six years ago an international team of physician scientists led a charge to advance clinical testing of the PARP inhibitor olaparib in cancer patients with known inherited BRCA mutatio...

Landmark CAR-T Cancer Study Published in the New England Journal of Medicine

Health : Newswise Medical News

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study results offer another boon for PARP inhibitors in treatment of advanced breast cancer

Academics / General Science : Science Codex

SAN ANTONIO - Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD...

New Mediola and OlympiAD Trial Results Offer Another Boon for PARP Inhibitors in Treatment of Advanced BRCA-Related Breast Cancer

Health : Newswise Medical News

Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD, executive di...

Comments


Copyright © 2016 Regator, LLC